Want to see DE:MAK full AI Analyst Report?

MATERNUS-Kliniken AG (MAK) Price & Analysis

2 Followers

MAK Stock Chart & Stats

€0.98

-€0.01(-0.71%)

At close: Jan 08 4:00 PM EST

€0.98

-€0.01(-0.71%)

Day’s Range― - ―

52-Week Range€0.81 - €10.90

Previous CloseN/A

Volume132.00

Average Volume (3M)618.00

Market Cap

€20.45M

Enterprise Value€199.25M

Total Cash (Recent Filing)€5.35M

Total Debt (Recent Filing)€183.19M

Price to Earnings (P/E)―

Beta0.53

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.76

Shares Outstanding20,970,000

10 Day Avg. Volume1,293

30 Day Avg. Volume618

Financial Highlights & Ratios

PEG Ratio-0.32

Price to Book (P/B)-0.27

Price to Sales (P/S)0.18

P/FCF Ratio1.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Recurring Revenue ModelMATERNUS’s core business is long‑term residential care where revenues come from recurring care reimbursements, resident co‑payments and accommodation charges. These predictable, contract‑like cash inflows support stable operating volumes and planning over multi‑month horizons.

Positive Operating Cash FlowConsistent positive operating cash flow and improving free cash flow (~€11.2M in 2025) provide internal liquidity to fund operations and modest capex. Sustained cash generation reduces immediate reliance on external financing and creates runway to implement restructuring or deleveraging.

Improving Operating TrendReported narrowing of losses across 2024–2025 indicates management has begun to improve operating efficiency or cost structure. If this trend is sustained, it supports a path toward break‑even by improving margins and leveraging fixed costs over time.

Bears Say

Very Weak Balance SheetNegative equity and debt exceeding assets create a structurally impaired capital base. This elevates refinancing and covenant risk, limits borrowing capacity, and constrains strategic options; long‑term recovery will likely require significant deleveraging or fresh capital to restore financial flexibility.

Sharp Revenue DeclineA ~33% YoY revenue drop materially reduces scale and operating leverage, pressuring margins and fixed‑cost coverage. Sustained revenue weakness undermines cash flow resilience and makes it harder to service high debt levels, forcing structural fixes in operations or revenue sources.

Persistent UnprofitabilityContinued negative net and operating margins mean the business has not achieved sustainable profitability. Ongoing losses erode capital further and increase dependence on either improved operations or external funding, raising solvency risk if improvements stall.

MAK FAQ

What was MATERNUS-Kliniken AG’s price range in the past 12 months?

MATERNUS-Kliniken AG lowest stock price was €0.81 and its highest was €10.90 in the past 12 months.

What is MATERNUS-Kliniken AG’s market cap?

MATERNUS-Kliniken AG’s market cap is €20.45M.

When is MATERNUS-Kliniken AG’s upcoming earnings report date?

MATERNUS-Kliniken AG’s upcoming earnings report date is Aug 20, 2026 which is in 27 days.

How were MATERNUS-Kliniken AG’s earnings last quarter?

MATERNUS-Kliniken AG released its earnings results on Apr 30, 2026. The company reported -€0.56 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.56.

Is MATERNUS-Kliniken AG overvalued?

According to Wall Street analysts MATERNUS-Kliniken AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does MATERNUS-Kliniken AG pay dividends?

MATERNUS-Kliniken AG does not currently pay dividends.

What is MATERNUS-Kliniken AG’s EPS estimate?

MATERNUS-Kliniken AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does MATERNUS-Kliniken AG have?

MATERNUS-Kliniken AG has 20,970,000 shares outstanding.

What happened to MATERNUS-Kliniken AG’s price movement after its last earnings report?

MATERNUS-Kliniken AG reported an EPS of -€0.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8%.

Which hedge fund is a major shareholder of MATERNUS-Kliniken AG?

Currently, no hedge funds are holding shares in DE:MAK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

MATERNUS-Kliniken AG Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

7.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

MATERNUS-Kliniken AG

Maternus-Kliniken AG oversees a network of facilities that includes retirement and nursing residences, rehabilitation centers, and a variety of specialized service companies. This enterprise primarily focuses on delivering geriatric care and medical rehabilitation services. Furthermore, it offers an extensive range of support options, such as emergency response systems, assisted living arrangements, and various care modalities including home care, residential care, temporary stays, and care for individuals with disabilities. Its services also encompass comprehensive rehabilitation and post-treatment programs. The company maintains roughly 23 establishments throughout Germany. Founded in 1877, Maternus-Kliniken AG's corporate headquarters are situated in Berlin, Germany.